Multiple financial institutions, including Morgan Stanley, Citigroup, and TD Cowen, boosted price targets and upgraded ratings on October 16, 2026.
1 report, 1 independent
Updated Oct 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Multiple financial institutions, including Morgan Stanley, Citigroup, and TD Cowen, boosted price targets and upgraded ratings on October 16, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
- Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.
- Goldman Sachs and Morgan Stanley noted that semiconductor stocks benefit from current rate levels but face market caution.
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
Related events
- TD Cowen provided analyst ratings and price targets for Werner Enterprises, while Citigroup also lifted its price target based on company performance.
- TD Cowen, Royal Bank of Canada, and Morgan Stanley all raised price targets and ratings for Ralliant.
- Royal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.